{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:53:41Z","timestamp":1792806821482,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.esmoop.2022.100612","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:04:24Z","timestamp":1668193464000},"page":"100612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib"],"prefix":"10.1016","volume":"7","author":[{"given":"R.","family":"Dziadziuszko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kurtsikidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Smoljanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100612_bib1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100612_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","article-title":"Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients","volume":"114","author":"Tian","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100612_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CLEP.S69718","article-title":"Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors","volume":"6","author":"Chia","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.esmoop.2022.100612_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/cancers12030693","article-title":"Imaging features and patterns of metastasis in non-small cell lung cancer with RET rearrangements","volume":"12","author":"Digumarthy","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2022.100612_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1759-7714.13017","article-title":"Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: comparison with EGFR mutation and ALK\/EGFR-negative lung cancer","volume":"10","author":"Mori","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.esmoop.2022.100612_bib6","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ijms21041416","article-title":"Brain metastases in lung cancers with emerging targetable fusion drivers","volume":"21","author":"Tan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2022.100612_bib7","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100612_bib12","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2014.05.020","article-title":"Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance","volume":"351","author":"Kodama","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2022.100612_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2022.100612_bib15","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.esmoop.2022.100612_bib16","author":"Food & Drug Administration (FDA)"},{"key":"10.1016\/j.esmoop.2022.100612_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00498254.2016.1179821","article-title":"Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects","volume":"47","author":"Morcos","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.esmoop.2022.100612_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/00498254.2017.1344910","article-title":"In\u00a0vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes","volume":"48","author":"Nakagawa","year":"2018","journal-title":"Xenobiotica"},{"key":"10.1016\/j.esmoop.2022.100612_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/cpdd.298","article-title":"Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.esmoop.2022.100612_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e20598","article-title":"Population pharmacokinetics (popPK) and exposure-response (ER) analyses to confirm alectinib 600 mg BID dose selection in a crizotinib-progressed or intolerant population","volume":"34","author":"Hsu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100612_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"139","author":"Nakagawa","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100612_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100527","article-title":"Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naive Japanese patients with ALK-positive non-small-cell lung cancer","volume":"7","author":"Hotta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2022.100612_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.esmoop.2022.100612_bib27","doi-asserted-by":"crossref","first-page":"1546P","DOI":"10.1093\/annonc\/mdz260.068","article-title":"Treatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) in US clinical practice","volume":"30","author":"Krebs","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib30","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib31","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1212\/NXI.0000000000000735","article-title":"Anaplastic lymphoma kinase inhibitor-associated myositis","volume":"7","author":"Uruha","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.esmoop.2022.100612_bib32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10637-016-0379-y","article-title":"The renal effects of ALK inhibitors","volume":"34","author":"Izzedine","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.esmoop.2022.100612_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100612_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","article-title":"Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies","volume":"79","author":"Morcos","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2022.100612_bib35","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.18632\/oncotarget.23840","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100612_bib36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pathol.2020.10.023","article-title":"Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding","volume":"53","author":"Kuzich","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.esmoop.2022.100612_bib37","doi-asserted-by":"crossref","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","article-title":"Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Aapro","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2022.100612_bib38","doi-asserted-by":"crossref","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","article-title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Larkin","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib39","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jtho.2019.02.015","article-title":"Renal effects of crizotinib in patients with ALK-positive advanced NSCLC","volume":"14","author":"Camidge","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100612_bib40","doi-asserted-by":"crossref","first-page":"1484PD","DOI":"10.1093\/annonc\/mdz260.006","article-title":"Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib versus crizotinib in untreated advanced ALK+ NSCLC","volume":"30","author":"Mok","year":"2019","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:26:13Z","timestamp":1718774773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2059702922002435"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100612","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100612"}}